Table 2.
Cumulative deviations in seven TB program indicators during March 2020 to March 2021 (pandemic period) compared to trends established during July 2018–February 2020 (baseline period).
| Indicator | Monthly Value During Baseline, Median (IQR) | Cumulative Predicated Value during Pandemic, Median (IQR) | Cumulative Observed Value during Pandemic | Cumulative Deviation from Expected, 95% PI | Cumulative Proportion Deviation from Expected, 95% PI |
|---|---|---|---|---|---|
| Outpatient department visits | 53,748 (50,455, 54,482) |
638,178 (584,386, 695,632) |
416,445 | −221,733.0 (−279,186.7, −167,940.9) |
−34.7% (−40.1%, −28.7%) |
| Presumed TB cases | 2357 (2209, 2626) | 34,947 (30,892, 39,422) |
18,837 | −16,109.5 (−20,585.4, −12,054.5) |
−46.1% (−52.2%, −39.0%) |
| Diagnosed TB cases | 249 (230, 257) | 3367 (2881, 3909) | 2064 | −1303.0 (−1844.8, −817.3) |
−38.7% (−47.2%, −28.4%) |
| Cases of TB/HIV co-infection | 54 (44, 71) | 1427 (1177, 1721) | 471 | −955.5 (−1250.2, −705.5) |
−67.0% (−72.6%, −60.0%) |
| Percentage of patients with successful treatment outcomes | 80 (76, 82) | 995 (841, 1174) | 974 | −21.0 (−200.0, 132.5) |
−2.1% (−17.0%, 15.8%) |
| Percentage of TB patients who died during treatment | 14 (13, 16) | 170 (112, 245) | 188 | 18.2 (−56.8, 76.7) | 10.7% (−23.2%, 68.8%) |
| Percentage of TB patients with unknown treatment outcomes | 6 (5, 9) | 177 (101, 310) | 138 | −38.7 (−171.7, 37.3) | −21.9% (−55.4%, 36.9%) |